TransCode Therapeutics receives Nasdaq delisting notice; hearing set for June 25, 2024

Transcode Therapeutics, Inc.

Nasdaq delisting notice due to failure to maintain minimum $1.00 bid price for 30 consecutive business days.
Company not eligible for second compliance period due to failure to meet $5M stockholders' equity requirement for initial listing.
Appealed delisting on May 14, 2024; delisting stayed pending final written decision after hearing on June 25, 2024.
Stock continues to trade on Nasdaq under symbol RNAZ; no assurance appeal will be successful.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.